Skip to main content
Log in

Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats

  • I. Cartilage degradation and osteoarthritis
  • Published:
Inflammation Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bradshaw D, Hill CH, Nixon JS, Wilkinson SE. Therapeutic potential of protein kinase C inhibitors. Agents Actions 1993;38:135–47.

    PubMed  Google Scholar 

  2. Berry N, Nishizuka Y. Protein kinase C and T cell activation. Eur J Biochem 1990;189:205–14.

    PubMed  Google Scholar 

  3. Birchall AM, Bishop J, Bradshaw D, Cline A, Coffey J, Elliot LH, et al. Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. J Pharmacol Exp Ther 1994;268:922–9.

    PubMed  Google Scholar 

  4. Prabhakar U, Lipshutz D, Pullen M, Turchin H, Kassis S, Nambi P. Protein kinase C regulates TNF-α production by human monocytes. Eur Cytokine Netw 1993;4:31–7.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

DiMartino, M., Wolff, C., Patil, A. et al. Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats. Inflamm Res 44 (Suppl 2), S123–S124 (1995). https://doi.org/10.1007/BF01778293

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01778293

Keywords

Navigation